SMS Pharmaceuticals (NSE:SMSPHARMA, BOM:532815) has received prequalification approval from the World Health Organisation (WHO) for its Unit VII manufacturing facility at Visakhapatnam in Andhra Pradesh, India.
This is expected to help the company increase its presence in the global market for Anti-Retroviral (ARV) active pharmaceutical ingredient, according to a Friday filing to the Indian stock exchanges.
The company's shares were up over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.